Highlights Hybio Pharmaceutical Co., Ltd.

Equities

300199

CNE1000011T7

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
12.45 ^CNY	-1.19%		+5.60%	-8.32%

05-21	Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	MT
04-26	Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	05-21	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	04-25	MT
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5%	04-18	MT
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	12-06	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	21/09/23	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23	CI
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules	17/05/23	MT
Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.	26/04/23	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	26/04/23	CI
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin.	27/03/23	CI
Li Xiulan agreed to acquire a 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin for approximately CNY 450 million.	13/02/23	CI
Hybio Pharma Registers New Pen Injector Medical Device	23/01/23	MT
Hybio Pharmaceutical Sees Loss of Up to 380 Million Yuan for 2022	18/01/23	MT
Hybio Pharmaceutical Gets Regulatory Nod for Diabetes Drug; Shares Drop 5%	16/01/23	MT
Hybio Pharma’s Diabetes Drug Passes Consistency Test; Shares Jump 6%	06/01/23	MT
Hybio Pharmaceutical Unit Gets Regulatory OK For Anti-Bleeding Drug; Shares Drop 8%	19/12/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hybio Pharmaceutical Co., Ltd.

Equities

300199

CNE1000011T7

Highlights

Filters